1 – 15 of 152
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data
2024) In Leukemia and Lymphoma(
- Contribution to journal › Article
-
Mark
Precision Diagnostics in Myeloid Malignancies : Development and Validation of a National Capture-Based Gene Panel
(
- Contribution to journal › Article
-
Mark
Hairy cell leukemia variant and WHO classification correspondence Re : 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms
(
- Contribution to journal › Debate/Note/Editorial
- 2023
-
Mark
Characterization of therapy-related acute myeloid leukemia : increasing incidence and prognostic implications
(
- Contribution to journal › Article
-
Mark
Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification
(
- Contribution to journal › Letter
-
Mark
The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
(
- Contribution to journal › Article
-
Mark
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
(
- Contribution to journal › Article
- 2022
-
Mark
A risk score based on real-world data to predict early death in acute promyelocytic leukemia
(
- Contribution to journal › Article
-
Mark
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Regional differences in treatment and outcome for myeloma patients in Sweden : A population based Swedish myeloma register study
(
- Contribution to journal › Article
-
Mark
Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia : Results from the HEAT-AML trial
(
- Contribution to journal › Article
- 2021
-
Mark
Combinatorial molecule screening identifies a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells
(
- Contribution to journal › Article
-
Mark
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML : The HOVON-SAKK-132 trial
(
- Contribution to journal › Article
-
Mark
Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? : A population-based study
(
- Contribution to journal › Article